The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
about
Targeting the insulin growth factor receptor 1CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesisMolecular mechanisms of ETS transcription factor-mediated tumorigenesisThe insulin-like growth factor system in cancerChildren's Oncology Group's 2013 blueprint for research: bone tumorsPotential approaches to the treatment of Ewing's sarcomaETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylationR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyPhase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupCixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialCharacterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group.New strategies in ewing sarcoma: lost in translation?Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growthIGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis.IGF-I receptor signalling in transformation and differentiation.Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.The contradictions of the insulin-like growth factor 1 receptor.Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.New therapeutic targets in soft tissue sarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Current therapeutic approaches in metastatic and recurrent ewing sarcomaPTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.Succinate dehydrogenase-deficient gastrointestinal stromal tumors.Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsExpression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies.Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphomaUnderstanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.Targeted therapies for advanced Ewing sarcoma family of tumors.Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.
P2860
Q24633750-A151BE7D-0957-4D21-A61C-229A85D8FECCQ24642797-C21E1B5A-0C09-4838-AA58-35D025F32B8CQ26829833-BA4DCB1F-A3D5-4BD7-8B7E-93DACA43846DQ27013945-E520BF83-48CF-49AD-BB52-6AAD30962802Q27027664-9763C5B8-DD3F-4134-B118-0ACB3A11CFF6Q28072744-9A17E1C4-A724-45EE-8A7A-A4BE1D6D7226Q28217452-67781E6C-686C-4401-B2FD-0A80207E9840Q33397796-011D0A04-89F3-4492-A1AA-9DD2E63FE322Q33398810-BB7A130D-1EE1-426C-9F73-F29A74E2A83CQ33406371-ABC6EBD7-8F34-4F9F-BB89-DA0C10C45571Q33408460-83506715-C421-4591-AB6A-B2ED200190E5Q33559559-94CE1A68-F059-4A7C-B318-8C6F5850E744Q33758471-C4739BF4-4029-4ED3-96B2-A47A7E7CEA4AQ33890792-21620CCA-057F-4A25-884F-4B26E79A28B5Q33904684-D1860DDD-4A65-48C5-8832-F61AACFFD375Q33911391-2563DD37-E9CC-4F29-92FB-303325889BBCQ33918687-F8D31A62-08EA-491A-A4D7-702FC3517019Q34021681-2395AD70-E3DD-41B4-9F16-E5B7EF99259AQ34059738-E5FED8D6-0D2A-4E80-8D8F-77812357E776Q34103628-40802E15-EB50-4A2B-9CAC-336196367B36Q34163784-257EFA1F-38CE-4316-942C-90F409699323Q34267924-1AD2396C-4124-4642-AF4D-1B3128A4300BQ34336988-5BBAD4DB-E738-4F81-A84F-22E6A5CE5C45Q34373180-91709665-93A9-4F87-994E-A334B78FEC88Q34518277-F185F3B8-B12A-4525-A7AE-288057445B17Q34668378-7D3B68BD-BB60-4A90-9627-062AFB70F4F8Q35013284-2AE7D246-46C3-4A7B-9DB8-45B408AE8BC0Q35018535-85F3FB71-2E76-446C-9E0C-66BAE6220261Q35037802-DCEE0B05-89E8-428C-872A-FAD946DE4076Q35058617-C8D93FF3-9BA3-449F-B48A-23EBE32A815DQ35556180-CFE49CF3-9113-4FF3-85D6-47011D0AE706Q35584126-B30C7EA4-899D-4A0F-9989-B4F6C9060E12Q35589492-EDC8F25F-5261-416D-B753-199A11551555Q35609719-B639D11B-7211-4982-8F88-E24DE8576A84Q35747809-0B8E5C3E-3170-46FF-9070-02F853BF9B6DQ35763861-0B05E983-7D78-40AF-897D-961E7AC7E519Q35809865-85D3C2CC-EC04-4002-B3AD-3C7944048BA2Q35880614-8909184D-2986-45B8-A7BB-6DC0FFBA8F99Q35957998-41860187-CE49-42AC-8477-EC1730632735Q35989688-A6E5435F-CA9B-45F7-868F-5E2C0B0F31FA
P2860
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The insulin-like growth factor ...... transformation of fibroblasts.
@en
type
label
The insulin-like growth factor ...... transformation of fibroblasts.
@en
prefLabel
The insulin-like growth factor ...... transformation of fibroblasts.
@en
P2093
P2860
P356
P1476
The insulin-like growth factor ...... transformation of fibroblasts.
@en
P2093
Blakesley V
Toretsky JA
P2860
P304
30822-30827
P356
10.1074/JBC.272.49.30822
P407
P577
1997-12-01T00:00:00Z